Data monitoring committees - Expect the unexpected

New England Journal of Medicine

Volumn 375, Issue 14, 2016, Pages 1365-1371

  DeMets, David L ^a   Ellenberg, Susan S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; METOPROLOL; PLACEBO; PROPRANOLOL; ROFECOXIB; SIMVASTATIN;

ADENOMATOUS POLYP; AORTA STENOSIS; CANCER RISK; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOL; COLON CANCER; CONGESTIVE HEART FAILURE; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REVIEW; RISK BENEFIT ANALYSIS; UNSTABLE ANGINA PECTORIS; CLINICAL TRIAL (TOPIC); MULTICENTER STUDY (TOPIC); NATIONAL HEALTH ORGANIZATION; STANDARDS; UNITED STATES;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; MULTICENTER STUDIES AS TOPIC; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

EID: 84990043625     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1510066     Document Type: Review

References (49)

1. Heart Special Project Committee. Organization, review, and administration of cooperative studies (Greenberg Report): a report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Control Clin Trials 1988; 9: 137-48.
2. Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: a practical perspective. New York: Wiley, 2003.
3. The establishment and operation of clinical trial data monitoring committees for clinical trial sponsors: guidance for clinical trial sponsors. Silver Spring, MD: Food and Drug Administration, March 2006 (http://www .fda .gov/ RegulatoryInformation/ Guidances/ ucm127069 .htm).
4. Meinert CL. Masked monitoring in clinical trials - blind stupidity? N Engl J Med 1998; 338: 1381-2.
5. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81.
6. The Coronary Drug Project Research Group. Practical aspects of decision making in clinical trials: the coronary drug project as a case study. Control Clin Trials 1981; 1: 363-76.
7. Canner PL. The Coronary Drug Project: monitoring of the data for evidence of adverse or beneficial treatment effects. Control Clin Trials 1983; 4: 467-83.
8. Practical issues in data monitoring of clinical trials: proceedings of a workshop, Bethesda, Maryland, 27-28 January 1992. Stat Med 1993; 12: 415-616.
9. DeMets DL, Fleming TR, Whitley RJ, et al. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. Control Clin Trials 1995; 16: 408-21.
10. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 2012; 307: 1838-47.
11. Fisher M, Roecker EB, DeMets D. The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Inf J 2001; 35: 115-29.
12. DeMets DL, Furberg C, Friedman LM. Data monitoring in clinical trials: a case studies approach. New York:, Springer, 2006.
13. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-14.
14. DeMets DL, Hardy R, Friedman LM, Lan KKG. Statistical aspects of early termination in the Beta-Blocker Heart Attack Trial. Control Clin Trials 1984; 5: 362-72.
15. Cairns J, Cohen L, Colton T, et al. Issues in the early termination of the aspirin component of the Physicians' Health Study. Ann Epidemiol 1991; 1: 395-405.
16. Wittes J, Barrett-Connor E, Braunwald E, et al. Monitoring the randomized trials of the Women's Health Initiative: the experience of the data and safety monitoring board. Clin Trials 2007; 4: 218-34.
17. DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet 1999; 354: 1983-8.
18. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
19. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
20. Fleming TR, Ellenberg SS, DeMets DL. Monitoring clinical trials: issues and controversies regarding confidentiality. Stat Med 2002; 21: 2843-51.
21. Fleming TR. Protecting the confidentiality of interim data: addressing current challenges. Clin Trials 2015; 12: 5-11.
22. DeMets DL. Relationships between data monitoring committees. Control Clin Trials 2000; 21: 54-5.
23. Fleming TR, Neaton JD, Goldman A, et al. Insights from monitoring the CPCRA didanosine/zalcitabine trial. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: Suppl 2: S9-18.
24. Armitage P. Data and safety monitoring in the Delta trial. Control Clin Trials 1999; 20: 229-41.
25. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.
26. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92.
27. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-56.
28. Mundy A. House panel seeks Vytorin study data. Wall Street Journal. August 1, 2008 (http://www .wsj .com/ articles/ SB121754522285302457).
29. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359: 1357-66.
30. Drazen JM, D'Agostino RB, Ware JH, Morrissey S, Curfman GD. Ezetimibe and cancer - an uncertain association. N Engl J Med 2008; 359: 1398-9.
31. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
32. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372: 1756-64.
33. Berenson A. Merck agrees to settle Vioxx suits for $4.85 billion. New York Times. November 9, 2007 (http://www .nytimes .com/ 2007/ 11/ 09/ business/ 09merck .html).
34. Tereskerz PM. Data safety monitoring boards: legal and ethical considerations for research accountability. Account Res 2010; 17: 30-50.
35. DeMets DL, Fleming TR, Rockhold F, et al. Liability issues for data monitoring committee members. Clin Trials 2004; 1: 525-31.
36. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971; 44: 793-7.
37. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612.
38. Pocock SJ. Group sequential methods in design and analysis of clinical trials. Biometrika 1977; 64: 191-200.
39. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.
40. Whitehead J. Sequential methods based on the boundaries approach for the clinical comparison of survival times. Stat Med 1994; 13: 1357-68, discussion 1369-70.
41. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
42. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233-44.
43. Wedel H, Demets D, Deedwania P, et al. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 2001; 142: 502-11.
44. Pocock S, Calvo G, Marrugat J, et al. International differences in treatment effect: do they really exist and why? Eur Heart J 2013; 34: 1846-52.
45. Bauchner H, Fontanarosa PB. Expression of concern: Kiel et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial - JAMA 2007;298(4):413-422.
46. JAMA 2012; 308: 2519.
47. Letter from Lisa Buchanan and Lisa A. Rooney, Office of the Secretary, Office of Public Health and Science, to Kathryn W. Irvine Tasker, Bruce E. Jarrell, and Evan D. Kharasch, June 21, 2011 (now archived at http://wayback .archive-it .org/ 4657/ 20150826185638/ http://www .hhs .gov/ ohrp/ compliance/ letters/ 2011 .html).
48. Kiel DP, Magaziner J, Zimmerman S, et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA 2007; 298: 413-22.
49. Clinical Trials Transformation Initiative (CTTI). CTTI Data Monitoring Committee Project expert meeting, Silver Spring, MD, July 28-29, 2015 (https:/ / www .ctti-clinicaltrials .org/ briefing-room/ meetings/ ctti-data-monitoring-committees -project-expert-meeting).